Back to All Events

Advances in motion highlights our identification of stathmin-2 as a novel therapeutic target in TDP43-mediated ALS/FTD

https://advances.massgeneral.org/neuro/journal.aspx?id=1188

Previous
January 14

Melamed et al. is published in Nature Neuroscience
Next
January 18

Alzforum highlights the manuscripts Melamed et al. and Klim et al. identifying TDP-43 mediated loss of Stathmin-2 in ALS